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been prevented by the currently availApproximately 250,000 women die every year of cervical cancers
V). Most of these could have
able prophylactic HPV vaccines.
Thousands of men and women also die every year of other HPV-
associated cancers, including cancers of the anus, vulva, vagina, penis
and oropharynx. Yet there are now HPV vaccines currently approved
for the prevention of cancers of the cervix, anus, vulva and vagina and
their precursor lesions.
These currently licensed HPV vaccines have been reviewed
extensively and scientiﬁcally, for efﬁcacy as well as safety. This was
ﬁrst reported from clinical trials that provided evidence supporting
licensure of the vaccines. As the vaccines have been incorporated into
public health programs in real world situations, they have continued
to show excellent safety and effectiveness outcomes.
The safety of these vaccines has been reviewed by multiple med-
ical authorities and regulatory agencies globally, including the World
Health Organisation [1] and its Global Advisory Committee on Vaccine
Safety (on multiple occasions [2]), Food and Drug Administration
(FDA) [3], European Medicines Agency (EMA) [4], and International
Federation of Gynaecology & Obstetrics (FIGO) [5]. Vaccine safety has
also been reviewed by health authorities in many individual countries
such as the Medicines & Healthcare Products Regulatory Agency of the
UK [MHRA] [6], the Therapeutic Goods Administration of Australia [7],
and Centres for Disease Control, USA [8,9]. All have endorsed them as
safe and effective. Importantly, there is no evidence for neurological or
autoimmune diseases caused by the HPV vaccines [10–13]. To date,
there have been no deaths directly attributed to HPV vaccination.
The International Papillomavirus Society (IPVS) is the world’s
leading professional society devoted to the study of papilloma-
viruses and the diseases that they cause [14]. IPVS is comprised of
basic scientists, clinical scientists, clinicians, public health experts,
epidemiologists, and community advocates. IPVS strongly endor-
ses HPV vaccination of all girls and women per the indications
speciﬁed by the relevant national regulatory authorities and vac-
cination of boys and men wherever already approved. IPVS urges
national regulatory authorities in countries where HPV vaccination
is not currently available to implement HPV vaccination in girls
and women as soon as possible and to strongly consider vacci-
nation of boys and men.
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